comparemela.com

Latest Breaking News On - Zentalis pharmaceuticals - Page 12 : comparemela.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Dec. 01, 2023 Zentalis® Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule.

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Director David Johnson s Strategic Purchase of Zentalis Pharmaceuticals Inc Shares

In the realm of stock market movements, insider trading activity is often a significant indicator that investors monitor to gauge the confidence of management and key stakeholders in the company's future.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded by Wedbush to Neutral

Wedbush lowered shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) from an outperform rating to a neutral rating in a research note released on Wednesday, MarketBeat reports. They currently have $12.00 price objective on the stock, down from their previous price objective of $38.00. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q4 2023 earnings at […]

HC Wainwright Trims Zentalis Pharmaceuticals (NASDAQ:ZNTL) Target Price to $46 00

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its target price reduced by HC Wainwright from $55.00 to $46.00 in a report published on Tuesday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q4 2023 earnings at ($0.83) EPS, FY2023 earnings at ($4.44) EPS, […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.